Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma [Phase 2]

View source ↗

Summary

Phase 2 trial of pazopanib hydrochloride in advanced or progressive malignant pheochromocytoma or paraganglioma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Status: TERMINATED | Results posted: 2016-07-21